Citations (69)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (21)
A. J. Potts, C. Cano, S. H. L. Thomas & S. L. Hill. (2020) Synthetic cannabinoid receptor agonists: classification and nomenclature. Clinical Toxicology 58:2, pages 82-98.
Read now
Read now
Xander M. R. Van Wijk, Robert Goodnough & Jennifer M. Colby. (2019) Mass spectrometry in emergency toxicology: Current state and future applications. Critical Reviews in Clinical Laboratory Sciences 56:4, pages 225-238.
Read now
Read now
Matilda Bäckberg, Madeleine Pettersson Bergstrand, Olof Beck & Anders Helander. (2019) Occurrence and time course of NPS benzodiazepines in Sweden – results from intoxication cases in the STRIDA project. Clinical Toxicology 57:3, pages 203-212.
Read now
Read now
Olof Beck, Matilda Bäckberg, Patrick Signell & Anders Helander. (2018) Intoxications in the STRIDA project involving a panorama of psychostimulant pyrovalerone derivatives, MDPV copycats. Clinical Toxicology 56:4, pages 256-263.
Read now
Read now
Daria Piacentino, Georgios D. Kotzalidis, Livia Longo, Antonio Pavan, Luciano Stivali, Guido Stivali, Stefano Ferracuti, Roberto Brugnoli, Paola Frati, Vittorio Fineschi, Paolo Girardi & Gabriele Sani. (2017) Body Image and Eating Disorders are Common among Professional and Amateur Athletes Using Performance and Image Enhancing Drugs: A Cross-Sectional Study. Journal of Psychoactive Drugs 49:5, pages 373-384.
Read now
Read now
Anders Helander, Matilda Bäckberg, Patrick Signell & Olof Beck. (2017) Intoxications involving acrylfentanyl and other novel designer fentanyls – results from the Swedish STRIDA project. Clinical Toxicology 55:6, pages 589-599.
Read now
Read now
Anders Helander & Matilda Bäckberg. (2017) New Psychoactive Substances (NPS) – the Hydra monster of recreational drugs. Clinical Toxicology 55:1, pages 1-3.
Read now
Read now
Matilda Bäckberg, Jenny Westerbergh, Olof Beck & Anders Helander. (2016) Adverse events related to the new psychoactive substance 3-fluorophenmetrazine – results from the Swedish STRIDA project. Clinical Toxicology 54:9, pages 819-825.
Read now
Read now
Olof Beck, Lisa Franzén, Matilda Bäckberg, Patrick Signell & Anders Helander. (2016) Toxicity evaluation of α-pyrrolidinovalerophenone (α-PVP): results from intoxication cases within the STRIDA project. Clinical Toxicology 54:7, pages 568-575.
Read now
Read now
Anders Helander, Matilda Bäckberg & Olof Beck. (2016) Intoxications involving the fentanyl analogs acetylfentanyl, 4-methoxybutyrfentanyl and furanylfentanyl: results from the Swedish STRIDA project. Clinical Toxicology 54:4, pages 324-332.
Read now
Read now
Derrick Lung, Nathan Wilson, Francois-Thibaut Chatenet, Clemence LaCroix & Roy Gerona. (2016) Non-targeted screening for novel psychoactive substances among agitated emergency department patients. Clinical Toxicology 54:4, pages 319-323.
Read now
Read now
Andrew Griffiths, Michelle Johnston & Lenore Hadley. (2016) MDPV in Queensland Drivers. Australian Journal of Forensic Sciences 48:2, pages 222-229.
Read now
Read now
Robert J. Tait, David Caldicott, David Mountain, Simon L. Hill & Simon Lenton. (2016) A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clinical Toxicology 54:1, pages 1-13.
Read now
Read now
Joseph J. Palamar, Mark K. Su & Robert S. Hoffman. (2016) Characteristics of novel psychoactive substance exposures reported to New York City Poison Center, 2011–2014. The American Journal of Drug and Alcohol Abuse 42:1, pages 39-47.
Read now
Read now
Olof Beck, Lisa Franzen, Matilda Bäckberg, Patrick Signell & Anders Helander. (2015) Intoxications involving MDPV in Sweden during 2010–2014: Results from the STRIDA project. Clinical Toxicology 53:9, pages 865-873.
Read now
Read now
Matilda Bäckberg, Olof Beck & Anders Helander. (2015) Phencyclidine analog use in Sweden—intoxication cases involving 3-MeO-PCP and 4-MeO-PCP from the STRIDA project. Clinical Toxicology 53:9, pages 856-864.
Read now
Read now
Matilda Bäckberg, Olof Beck, Karl-Henrik Jönsson & Anders Helander. (2015) Opioid intoxications involving butyrfentanyl, 4-fluorobutyrfentanyl, and fentanyl from the Swedish STRIDA project. Clinical Toxicology 53:7, pages 609-617.
Read now
Read now
Anders Helander, Olof Beck & Matilda Bäckberg. (2015) Intoxications by the dissociative new psychoactive substances diphenidine and methoxphenidine. Clinical Toxicology 53:5, pages 446-453.
Read now
Read now
Matilda Bäckberg, Erik Lindeman, Olof Beck & Anders Helander. (2015) Characteristics of analytically confirmed 3-MMC-related intoxications from the Swedish STRIDA project. Clinical Toxicology 53:1, pages 46-53.
Read now
Read now
A. Helander, M. Bäckberg & O. Beck. (2014) MT-45, a new psychoactive substance associated with hearing loss and unconsciousness. Clinical Toxicology 52:8, pages 901-904.
Read now
Read now
M. Bäckberg, O. Beck, P. Hultén, J. Rosengren-Holmberg & A. Helander. (2014) Intoxications of the new psychoactive substance 5-(2-aminopropyl)indole (5-IT): A case series from the Swedish STRIDA project. Clinical Toxicology 52:6, pages 618-624.
Read now
Read now
Articles from other publishers (48)
Bartłomiej Feigel, Piotr Adamowicz & Sławomir Wybraniec. (2023) Recent advances in analysis of new psychoactive substances by means of liquid chromatography coupled with low-resolution tandem mass spectrometry. Analytical and Bioanalytical Chemistry.
Crossref
Crossref
Matilda Bäckberg, Svante Vikingsson, Joakim Strandberg, Sara Wall, Anna Åstrand, Hanna Karlsson, Mattias Persson, Robert Kronstrand & Henrik Green. (2023) Using in vitro receptor activity studies of synthetic cannabinoids to support the risk assessment of new psychoactive substances – A Swedish strategy to protect public health from harm. Forensic Science International 348, pages 111691.
Crossref
Crossref
Gabriel Gatica-Bahamonde, Elizabeth Alexandra Godynyuk, Jessica Neicun, Emmert Roberts, Mehmet Mikail Tangerli, Robin van Kessel, Katarzyna Czabanowska, Keith Humphreys & Andres Roman-Urrestarazu. (2023) Analysing the use trends of new psychoactive substances using wastewater-based epidemiology in Europe: A systematic review. Emerging Trends in Drugs, Addictions, and Health 3, pages 100053.
Crossref
Crossref
Lea Wagmann, Sascha K Manier & Markus R Meyer. (2022) Can the Intake of a Synthetic Tryptamine be Detected Only by Blood Plasma Analysis? A Clinical Toxicology Case Involving 4-HO-MET. Journal of Analytical Toxicology 46:5, pages 567-572.
Crossref
Crossref
John R.H. Archer. 2022. Novel Psychoactive Substances. Novel Psychoactive Substances
131
156
.
Bobby P Smyth, Anne O’Farrell & Walter Cullen. (2021) Drug-related medical hospital admissions during and after a period of head shop expansion. European Journal of Public Health 31:2, pages 285-291.
Crossref
Crossref
Te-I Weng, Lian-Yu Chen, Ju-Yu Chen, Pai-Shan Chen, Hsaio-Lin Hwa & Cheng-Chung Fang. (2020) Characteristics of analytically confirmed illicit substance-using patients in the Emergency Department. Journal of the Formosan Medical Association 119:12, pages 1827-1834.
Crossref
Crossref
Anders Helander, Matilda Bäckberg & Olof Beck. (2020) Drug trends and harm related to new psychoactive substances (NPS) in Sweden from 2010 to 2016: Experiences from the STRIDA project. PLOS ONE 15:4, pages e0232038.
Crossref
Crossref
Camille Ramos, Amira Guirguis, Nigel Smeeton, Hadar Zaman, Anna-Marie Felice, Stephanie Bancroft, Rosalind Gittins, Gill Hawksworth, John Martin Corkery & Fabrizio Schifano. (2020) Exploring the Baseline Knowledge and Experience of Healthcare Professionals in the United Kingdom on Novel Psychoactive Substances. Brain Sciences 10:3, pages 142.
Crossref
Crossref
Sabrina Lehmann, Tobias Kieliba, Mario Thevis, Markus A. Rothschild & Katja Mercer-Chalmers-Bender. (2019) Fatalities associated with NPS stimulants in the Greater Cologne area. International Journal of Legal Medicine 134:1, pages 229-241.
Crossref
Crossref
Asha Shabani Ripanda, Bajarang Bal Lal Srivastava, Said Hamad Vuai & Azan A Nyundo. (2019) Prevalence and factors associated with continual opioid use among patients attending methadone clinic at Mwananyamala Hospital, Dar Es Salaam, Tanzania. Forensic Science International: Reports 1, pages 100037.
Crossref
Crossref
Paul J Jannetto, Anders Helander, Uttam Garg, Gregory C Janis, Bruce Goldberger & Hemamalini Ketha. (2019) The Fentanyl Epidemic and Evolution of Fentanyl Analogs in the United States and the European Union. Clinical Chemistry 65:2, pages 242-253.
Crossref
Crossref
Madeleine Pettersson Bergstrand, Olof Beck & Anders Helander. (2018) Urine analysis of 28 designer benzodiazepines by liquid chromatography–high-resolution mass spectrometry. Clinical Mass Spectrometry 10, pages 25-32.
Crossref
Crossref
Lisa Franzén, Matilda Bäckberg, Olof Beck & Anders Helander. (2018) Acute Intoxications Involving α-Pyrrolidinobutiophenone (α-PBP): Results from the Swedish STRIDA Project. Journal of Medical Toxicology 14:4, pages 265-271.
Crossref
Crossref
Anders Helander, Katarina Stojanovic, Tomas Villén & Olof Beck. (2018) Detectability of fentanyl and designer fentanyls in urine by 3 commercial fentanyl immunoassays. Drug Testing and Analysis 10:8, pages 1297-1304.
Crossref
Crossref
Craig McKenzie, Oliver B. Sutcliffe, Kevin D. Read, Paul Scullion, Ola Epemolu, Daniel Fletcher, Anders Helander, Olof Beck, Alexia Rylski, Lysbeth H. Antonides, Jennifer Riley, Shannah A. Smith & Niamh Nic Daeid. (2018) Chemical synthesis, characterisation and in vitro and in vivo metabolism of the synthetic opioid MT-45 and its newly identified fluorinated analogue 2F-MT-45 with metabolite confirmation in urine samples from known drug users. Forensic Toxicology 36:2, pages 359-374.
Crossref
Crossref
Michael Chary, David Yi & Alex F. Manini. (2018) Candyflipping and Other Combinations: Identifying Drug–Drug Combinations from an Online Forum. Frontiers in Psychiatry 9.
Crossref
Crossref
Madeleine Pettersson Bergstrand, Markus R. Meyer, Olof Beck & Anders Helander. (2018) Human urinary metabolic patterns of the designer benzodiazepines flubromazolam and pyrazolam studied by liquid chromatography-high resolution mass spectrometry. Drug Testing and Analysis 10:3, pages 496-506.
Crossref
Crossref
Matilda Bäckberg, Karl-Henrik Jönsson, Olof Beck & Anders Helander. (2018) Investigation of drug products received for analysis in the Swedish STRIDA project on new psychoactive substances. Drug Testing and Analysis 10:2, pages 340-349.
Crossref
Crossref
Anders Helander & Matilda Bäckberg. 2018. New Psychoactive Substances. New Psychoactive Substances
461
473
.
Marie Claire Van Hout & Evelyn Hearne. (2016) User Experiences of Development of Dependence on the Synthetic Cannabinoids, 5f-AKB48 and 5F-PB-22, and Subsequent Withdrawal Syndromes. International Journal of Mental Health and Addiction 15:3, pages 565-579.
Crossref
Crossref
Anders Helander. 2017. Detection of Drug Misuse: Biomarkers, Analytical Advances and Interpretation. Detection of Drug Misuse: Biomarkers, Analytical Advances and Interpretation
83
99
.
A. Helander, M. Bradley, A. Hasselblad, L. Norlén, I. Vassilaki, M. Bäckberg & J. Lapins. (2017) Acute skin and hair symptoms followed by severe, delayed eye complications in subjects using the synthetic opioid MT-45. British Journal of Dermatology 176:4, pages 1021-1027.
Crossref
Crossref
David J. Lowe, Hazel J. Torrance, Alastair J. Ireland, Felix Bloeck & Richard Stevenson. (2017) SODAS. European Journal of Emergency Medicine 24:2, pages 126-129.
Crossref
Crossref
Madeleine Pettersson Bergstrand, Anders Helander, Therese Hansson & Olof Beck. (2017) Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays. Drug Testing and Analysis 9:4, pages 640-645.
Crossref
Crossref
Matilda Bäckberg, Luiza Tworek, Olof Beck & Anders Helander. (2016) Analytically Confirmed Intoxications Involving MDMB-CHMICA from the STRIDA Project. Journal of Medical Toxicology 13:1, pages 52-60.
Crossref
Crossref
R Le Boisselier, J Alexandre, V Lelong‐Boulouard & D Debruyne. (2016) Focus on cannabinoids and synthetic cannabinoids. Clinical Pharmacology & Therapeutics 101:2, pages 220-229.
Crossref
Crossref
Khalid A. Alsenedi & Calum Morrison. (2017) Comparison of six derivatizing agents for the determination of nine synthetic cathinones using gas chromatography-mass spectrometry. Analytical Methods 9:18, pages 2732-2743.
Crossref
Crossref
A. Helander. 2017. Handbook of Cannabis and Related Pathologies. Handbook of Cannabis and Related Pathologies
839
847
.
Juliet Kinyua, Noelia Negreira, Bram Miserez, Ana Causanilles, Erik Emke, Lies Gremeaux, Pim de Voogt, John Ramsey, Adrian Covaci & Alexander L.N. van Nuijs. (2016) Qualitative screening of new psychoactive substances in pooled urine samples from Belgium and United Kingdom. Science of The Total Environment 573, pages 1527-1535.
Crossref
Crossref
Madeleine Pettersson Bergstrand, Anders Helander & Olof Beck. (2016) Development and application of a multi-component LC–MS/MS method for determination of designer benzodiazepines in urine. Journal of Chromatography B 1035, pages 104-110.
Crossref
Crossref
Markus R. Meyer. (2016) New psychoactive substances: an overview on recent publications on their toxicodynamics and toxicokinetics. Archives of Toxicology 90:10, pages 2421-2444.
Crossref
Crossref
Anna Rickli, Olivier D. Moning, Marius C. Hoener & Matthias E. Liechti. (2016) Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. European Neuropsychopharmacology 26:8, pages 1327-1337.
Crossref
Crossref
Markus R. Meyer, Madeleine Pettersson Bergstrand, Anders Helander & Olof Beck. (2016) Identification of main human urinary metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxipam by nano-liquid chromatography-high-resolution mass spectrometry for drug testing purposes. Analytical and Bioanalytical Chemistry 408:13, pages 3571-3591.
Crossref
Crossref
Cristina Miliano, Giovanni Serpelloni, Claudia Rimondo, Maddalena Mereu, Matteo Marti & Maria Antonietta De Luca. (2016) Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants. Frontiers in Neuroscience 10.
Crossref
Crossref
Johanna J. Nugteren-van Lonkhuyzen, Antoinette J.H.P. van Riel, Tibor M. Brunt & Laura Hondebrink. (2015) Pharmacokinetics, pharmacodynamics and toxicology of new psychoactive substances (NPS): 2C-B, 4-fluoroamphetamine and benzofurans. Drug and Alcohol Dependence 157, pages 18-27.
Crossref
Crossref
Joseph J. Palamar, Silvia S. Martins, Mark K. Su & Danielle C. Ompad. (2015) Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting. Drug and Alcohol Dependence 156, pages 112-119.
Crossref
Crossref
C. Lovett, D. M. Wood & P. I. Dargan. (2015) Pharmacology and toxicology of the synthetic cannabinoid receptor agonistsPharmacologie et toxicologie des agonistes synthétiques des récepteurs cannabinoïdes. Réanimation 24:5, pages 527-541.
Crossref
Crossref
Anders Ledberg. (2015) The interest in eight new psychoactive substances before and after scheduling. Drug and Alcohol Dependence 152, pages 73-78.
Crossref
Crossref
Magdalene H.Y. Tang, C.K. Ching, Caroline Y.W. Lee, Ying-Hoo Lam & Tony W.L. Mak. (2014) Simultaneous detection of 93 conventional and emerging drugs of abuse and their metabolites in urine by UHPLC-MS/MS. Journal of Chromatography B 969, pages 272-284.
Crossref
Crossref
Anders Helander, Matilda Bäckberg, Peter Hultén, Yasir Al-Saffar & Olof Beck. (2014) Detection of new psychoactive substance use among emergency room patients: Results from the Swedish STRIDA project. Forensic Science International 243, pages 23-29.
Crossref
Crossref
Olof Beck & Magnus Ericsson. (2014) Methods for urine drug testing using one-step dilution and direct injection in combination with LC–MS/MS and LC–HRMS. Bioanalysis 6:17, pages 2229-2244.
Crossref
Crossref
Frank T Peters. (2014) Recent developments in urinalysis of metabolites of new psychoactive substances using LC–MS. Bioanalysis 6:15, pages 2083-2107.
Crossref
Crossref
Esther Papaseit, Magí Farré, Fabrizio Schifano & Marta Torrens. (2014) Emerging drugs in Europe. Current Opinion in Psychiatry 27:4, pages 243-250.
Crossref
Crossref
Jolanta B. Zawilska. (2014) Mephedrone and other cathinones. Current Opinion in Psychiatry 27:4, pages 256-262.
Crossref
Crossref
D. M. Wood, S. L. Hill, S. H. L. Thomas & P. I. Dargan. (2014) Using poisons information service data to assess the acute harms associated with novel psychoactive substances. Drug Testing and Analysis 6:7-8, pages 850-860.
Crossref
Crossref
Christophe Soussan & Anette Kjellgren. (2017) The Flip Side of “Spice”: The Adverse Effects of Synthetic Cannabinoids as Discussed on a Swedish Internet Forum. Nordic Studies on Alcohol and Drugs 31:2, pages 207-220.
Crossref
Crossref
Olof Beck, Linnea Rausberg, Yasir Al-Saffar, Tomas Villen, Lennart Karlsson, Therese Hansson & Anders Helander. (2014) Detectability of new psychoactive substances, ‘legal highs’, in CEDIA, EMIT, and KIMS immunochemical screening assays for drugs of abuse. Drug Testing and Analysis, pages n/a-n/a.
Crossref
Crossref